Mutant fragments of ospa and methods and uses relating thereto
US-2016333056-A1 · Nov 17, 2016 · US
US10125177B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10125177-B2 |
| Application number | US-201815865594-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 9, 2018 |
| Priority date | Jan 13, 2011 |
| Publication date | Nov 13, 2018 |
| Grant date | Nov 13, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
A Treponema pallidum triplet antigen construct is disclosed which includes three Treponema pallidum antigens (TP15, TP17, and TP47), as well as a ten amino acid leader sequence (tag 261) and human copper zinc superoxide dismutase (hSOD). This construct is optimized for in vitro diagnosis of syphilis infection. Plasmids containing DNA encoding the triplet antigen, host cells, production methods, detection methods, and kits are also disclosed.
Opening claim text (preview).
The invention claimed is: 1. A Treponema pallidum triplet antigen comprising the amino acid sequence as shown in SEQ ID NO:10. 2. The Treponema pallidum triplet antigen of claim 1 labeled with a detectable marker. 3. The Treponema pallidum triplet antigen of claim 2 wherein the detectable marker is horseradish peroxidase. 4. A kit for detection of Treponema pallidum antibodies, the kit comprising: the Treponema pallidum triplet antigen of claim 1 ; and a second Treponema pallidum triplet antigen of claim 1 , the second Treponema pallidum triplet antigen labeled with a detectable marker. 5. The kit of claim 4 further comprising positive or negative controls. 6. The kit of claim 4 further comprising calibration samples. 7. The kit of claim 4 further comprising one or more of enzyme conjugate, substrate for enzyme conjugate, buffer solution, and washing solution. 8. A method of detecting the presence of Treponema pallidum antibodies in a sample, the method comprising: contacting the sample with a first antigen which is immobilized on a solid support and which comprises the Treponema pallidum triplet antigen of claim 1 , wherein Treponema pallidum antibodies present in the sample bind to the Treponema pallidum triplet antigen forming an antibody/antigen complex; and detecting the antibody/antigen complex, thereby detecting the presence of Treponema pallidum antibodies.
for venereal disease, e.g. syphilis, gonorrhoea {(herpes G01N33/56994; chlamydia G01N33/56927)} · CPC title
containing a tag for immunodetection, or an epitope for immunisation · CPC title
Bacteria · CPC title
Fusion polypeptide · CPC title
from Spirochaetales (O), e.g. Treponema, Leptospira · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.